title: The protective effect of KCNMB1 E65K against hypertension is restricted to blood pressure treatment with beta-blockade.
authors.forename: A
authors.initials: A
authors.lastname: Kelley-Hedgepeth
authors.forename: I
authors.initials: I
authors.lastname: Peter
authors.forename: Ke
authors.initials: K
authors.lastname: Kip
authors.forename: Mc
authors.initials: M
authors.lastname: Montefusco
authors.forename: S
authors.initials: S
authors.lastname: Kogan
authors.forename: D
authors.initials: D
authors.lastname: Cox
authors.forename: Jm
authors.initials: J
authors.lastname: Ordovas
authors.forename: D
authors.initials: D
authors.lastname: Levy
authors.forename: Se
authors.initials: S
authors.lastname: Reis
authors.forename: Me
authors.initials: M
authors.lastname: Mendelsohn
authors.forename: D
authors.initials: D
authors.lastname: Housman
authors.forename: Gs
authors.initials: G
authors.lastname: Huggins
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D001794:Blood Pressure / Q000235:genetics*; D015331:Cohort Studies; D005260:Female; D005787:Gene Frequency / Q000235:genetics; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000235:genetics*; D051038:Large-Conductance Calcium-Activated Potassium Channel beta Subunits / Q000235:genetics*; D008297:Male; D011110:Polymorphism, Genetic / Q000235:genetics*; D044465:White People / Q000235:genetics
chemical_list: D000319:Adrenergic beta-Antagonists; C531905:KCNMB1 protein, human; D051038:Large-Conductance Calcium-Activated Potassium Channel beta Subunits